Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Aadi Bioscience, Inc. ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, ...
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Beasley Broadcast Group, Inc. ("Beasley" or the "Company"), a multi-platform media company, announced today that it will report its 2024 full-year financial results before the market opens on Thursday ...
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...
Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results